Skip to main content
Premium Trial:

Request an Annual Quote

Chromatide Closes VC Round with Existing Investors

NEW YORK (GenomeWeb News) — UK-based synthetic polymer company Chromatide said today that it has received an undisclosed second round of financing from Enterprise Ventures and Alliance Fund Managers, both of which invested in it in 2007.

Chromatide, which plans to use the money to continue expanding its IP portfolio, said that since the first investment it has "successfully delivered on a range of technical and commercial" milestones.

CEO Clare Hildred said in a statement that the company is using its expertise to develop a range of new technologies for biomolecule purification, polymer synthesis, chemical processes, and instrument design.

AFM offers loans and equity packages ranging from £3,000 ($4,300) to £4 million to businesses located in Merseyside, UK.

EV is an independent fund manager that provides private equity and venture capital to regional groups located throughout Northern England and the Midlands region.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.